Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: An EPCRC opioid guidelines project

Palliative Medicine

Volumn 25, Issue 5, 2011, Pages 578-596

  Radbruch, Lukas ^a,e   Trottenberg, Peter ^b   Elsner, Frank ^b   Kaasa, Stein ^c   Caraceni, Augusto ^d  

^a UNIVERSITY OF BONN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Neoplasm; opioids; pain

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; FENTANYL; HYDROMORPHONE; KETOBEMIDONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; SUFENTANIL;

ANALGESIA; ANXIETY; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE SWELLING; BLURRED VISION; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CONFERENCE PAPER; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG ADMINISTRATION ROUTE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EUPHORIA; FATIGUE; HALLUCINATION; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MOOD DISORDER; MYOCLONUS; NAUSEA; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SOMNOLENCE; SWEATING; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VERTIGO; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; EUROPE; HUMANS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 79959907952     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216310383739     Document Type: Conference Paper

References (62)

1. Cancer Pain Relief. Geneva: World Health Organization ; 1986 :
2. Cancer Pain Relief: With a Guide to Opioid Availability. 2 nd edn Geneva: World Health Organization ; 1996 :
3. Cancer Pain Relief and Palliative Care in Children. Geneva: World Health Organization ; 1999 :
4. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001 ; 84: 587-593 (Pubitemid 32238990)
5. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995 ; 76: 1283-1293
6. Bishop MF, Stephens L, Goodrich M, Byock I. Medication kits for managing symptomatic emergencies in the home: a survey of common hospice practice. J Palliat Med. 2009 ; 12: 37-44
7. Kotani K. Morphine use for at-home cancer patients in Japan. Tohoku J Exp Med. 2004 ; 204: 119-123 (Pubitemid 39335050)
8. Rawal N, Hylander J, Arner S. Management of terminal cancer pain in Sweden: a nationwide survey. Pain. 1993 ; 54: 169-179 (Pubitemid 23231931)
9. Maier R, Maier A, Muller-Busch C. [Outpatient opiate therapy in cancer patients during their last days of life]. Schmerz. 2008 ; 22: 148: 150-155
10. Chinellato A, Terrazzani G, Debetto P, et al. Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian region. Br J Clin Pharmacol. 2006 ; 62: 130-133 (Pubitemid 44195249)
11. Caraceni A, De Conno F, Kaasa S, Radbruch L, Hanks G. Update on cancer pain guidelines. J Pain Symptom Manage. 2009 ; 38 (3). e1 - e3
12. Kaasa S, Loge JH, Fayers P, et al. Symptom assessment in palliative care: a need for international collaboration. J Clin Oncol. 2008 ; 26: 3867-3873
13. Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at end-of-life. Ann Pharmacother. 2004 ; 38: 1015-1023 (Pubitemid 38657746)
14. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002 ; 1: CD003447 - CD003447
15. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007 ; 4: CD003868 - CD003868
16. Moulin DE, Johnson NG, Murray-Parsons N, Geoghegan MF, Goodwin VA, Chester MA. Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use. Cmaj. 1992 ; 146: 891-897
17. Watanabe S, Pereira J, Hanson J, Bruera E. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study. J Pain Symptom Manage. 1998 ; 16: 323-326 (Pubitemid 28545913)
18. Hunt R, Fazekas B, Thorne D, Brooksbank M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 1999 ; 18: 111-119 (Pubitemid 29409439)
19. Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain. 1996 ; 67: 443-449 (Pubitemid 26375362)
20. Miller MG, McCarthy N, O'Boyle CA, Kearney M. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. J Pain Symptom Manage. 1999 ; 18: 9-16 (Pubitemid 29344631)
21. Nelson KA, Glare PA, Walsh D, Groh ES. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997 ; 13: 262-267 (Pubitemid 27240679)
22. Vanier MC, Labrecque G, Lepage-Savary D, Poulin E, Provencher L, Lamontagne C. Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study. Pain. 1993 ; 53: 27-32 (Pubitemid 23137263)
23. Bruera E, Brenneis C, Michaud M, MacMillan K, Hanson J, MacDonald RN. Patient-controlled subcutaneous hydromorphone versus continuous subcutaneous infusion for the treatment of cancer pain. J Natl Cancer Inst. 1988 ; 80: 1152-1154
24. Lang AH, Abbrederis K, Dzien A, Drexel H. Treatment of severe cancer pain by continuous infusion of subcutaneous opioids. Recent Results Cancer Res. 1991 ; 121: 51-57
25. Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet. 1991 ; 337: 465-468
26. Kerr IG, Sone M, Deangelis C, Iscoe N, MacKenzie R, Schueller T. Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients. Ann Intern Med. 1988 ; 108: 554-557
27. Houde RW Advances in Pain Research and Therapy. Foley KM Inturrisi C, ed. New York: Raven Press ; 1986: 129-135.
28. Elsner F, Radbruch L, Loick G, Gartner J, Sabatowski R. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliat Med. 2005 ; 8: 743-750 (Pubitemid 41266250)
29. Drexel H. Long-term continuous subcutaneous and intravenous opioid infusions. Lancet. 1991 ; 337: 979-979
30. Koshy RC, Kuriakose R, Sebastian P, Koshy C. Continuous morphine infusions for cancer pain in resource-scarce environments: comparison of the subcutaneous and intravenous routes of administration. J Pain Palliat Care Pharmacother. 2005 ; 19: 27-33 (Pubitemid 40594047)
31. Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke AC. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol. 1995 ; 13: 1520-1527
32. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 1995 ; 62: 141-146
33. Campbell CF, Mason JB, Weiler JM. Continuous subcutaneous infusion of morphine for the pain of terminal malignancy. Ann Intern Med. 1983 ; 98: 51-52 (Pubitemid 13217966)
34. Walsh D, Perin ML, McIver B. Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use. Am J Hosp Palliat Care. 2006 ; 23: 353-359
35. Enting RH, Oldenmenger WH, van der Rijt CC, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer. 2002 ; 94: 3049-3056 (Pubitemid 34547707)
36. Ellershaw JE, Kinder C, Aldridge J, Allison M, Smith JC. Care of the dying: is pain control compromised or enhanced by continuation of the fentanyl transdermal patch in the dying phase?. J Pain Symptom Manage. 2002 ; 24: 398-403 (Pubitemid 36020483)
37. Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E. The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer. 1999 ; 7: 265-270 (Pubitemid 29302635)
38. Watanabe S, Belzile M, Kuehn N, Hanson J, Bruera E. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Cancer Treat Rev. 1996 ; 22(Suppl. A): 131-136
39. Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg. 1995 ; 80: 296-302
40. Kornick CA, Santiago-Palma J, Schulman G, et al. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. Cancer. 2003 ; 97: 3121-3124 (Pubitemid 36676269)
41. Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain. 1997 ; 69: 191-198 (Pubitemid 27081425)
42. Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer. 2001 ; 92: 3056-3061 (Pubitemid 33136201)
43. Zech DF, Grond SU, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain. 1992 ; 50: 293-301
44. Takahashi M, Ohara T, Yamanaka H, Shimada A, Nakaho T, Makoto Y. The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment. Palliat Med. 2003 ; 17: 673-678 (Pubitemid 37508951)
45. Meuret G, Jocham H. Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients. Cancer Treat Rev. 1996 ; 22(Suppl. A): 137-140
46. Ferris, FD, Kerr IG, De Angelis C et al. Inpatient narcotic infusions for patients with cancer pain. J Palliat Care 1990; 6(2): 51-59.
47. De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995 ; 13: 1004-1008
48. Mizguchi K, Takeda F, Hiraga K, Nakashima M. Utility evaluation of morphine hydrocloride suppository in the treatment of cancer pain. Rinshou Igaku. 1990 ; 6: 2357-2376
49. Pannuti F, Rossi AP, Iafelice G, et al. Control of chronic pain in very advanced cancer patients with morphine hydrochloride administered by oral, rectal and sublingual route. Clinical report and preliminary results on morphine pharmacokinetics. Pharmacol Res Commun. 1982 ; 14: 369-380 (Pubitemid 12007174)
50. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage. 1997 ; 13: 254-261 (Pubitemid 27240678)
51. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin. 2003 ; 19: 457-469 (Pubitemid 37122037)
52. Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin. 1997 ; 35: 25-32 (Pubitemid 127735941)
53. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006 ; 28: 943-952 (Pubitemid 44062699)
54. Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage. 2008 ; 36: 117-125 (Pubitemid 352010492)
55. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003 ; 25: 150-168 (Pubitemid 36206743)
56. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004 ; 26: 1808-1820 (Pubitemid 40089494)
57. Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009 ; 144: 218-222
58. Burton AW, Driver LC, Mendoza TR, Syed G. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series. Clin J Pain. 2004 ; 20: 195-197 (Pubitemid 38544040)
59. Bushnaq M, Al-Shoubaki M, Milhem M. The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer. J Palliat Med. 2009 ; 12: 511-514
60. Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007 ; 96: 1828-1833 (Pubitemid 46912022)
61. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009 ; 25: 2805-2815
62. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009 ; 31: 1177-1191